Enveric Biosciences, Inc. ENVB

ENVB Company Overview

Enveric Biosciences, Inc. is a U.S.-based biotechnology company focused on developing next-generation neuroplastogenic and psychedelic-inspired therapeutics for the treatment of mental health and neurological disorders. The company operates within the biopharmaceutical and drug development industries, with an emphasis on creating compounds intended to address conditions such as anxiety, depression, and addiction while seeking to reduce or eliminate hallucinogenic side effects associated with traditional psychedelic compounds. Enveric’s primary revenue-related activities remain tied to research and development initiatives, intellectual property licensing potential, and capital market financing, as the company is currently in the clinical and preclinical development stage rather than commercial pharmaceutical sales.

The company evolved through a strategic transition from its earlier oncology-focused business model into a neuroscience and mental health therapeutics platform. Public filings and investor disclosures indicate that Enveric increasingly concentrated its resources on cannabinoid-derived and psychedelic-inspired compounds, including proprietary molecular libraries and patent-backed development programs. Its positioning centers on developing non-hallucinogenic neuroplastogens and differentiated intellectual property in a rapidly expanding psychiatric therapeutics market, where there is increasing industry interest in novel mechanisms for treatment-resistant mental health disorders.